Nasdaq

Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation Therapy to Address Uncontrolled Hypertension

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...
Nasdaq

Orchestra BioMed Hosts Symposium on Breakthrough AVIM Therapy for Uncontrolled Hypertension at HRS 2025 Annual Meeting

The FDA has granted Breakthrough Device Designation to Orchestra BioMed's Atrioventricular Interval Modulation (AVIM) therapy, aimed at treating patients with uncontrolled hypertension who are at ...
The American Journal of Managed Care

Q&A: Novel Therapy Holds Promise for Hypertension Treatment in Patients With Pacemakers

Atrioventricular interval modulation (AVIM) therapy for hypertension may help address this common comorbidity among patients with pacemakers. For patients with pacemakers, hypertension is a common ...
Morningstar

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and ...

Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the ...
TCTMD

Effects of AtrioVentricular Interval Modulation (AVIM) Therapy in Subjects With Hypertension and Diastolic Dysfunction

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by ...